[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CR20150266A - Formulaciones de liberación modificada para oprozomib - Google Patents

Formulaciones de liberación modificada para oprozomib

Info

Publication number
CR20150266A
CR20150266A CR20150266A CR20150266A CR20150266A CR 20150266 A CR20150266 A CR 20150266A CR 20150266 A CR20150266 A CR 20150266A CR 20150266 A CR20150266 A CR 20150266A CR 20150266 A CR20150266 A CR 20150266A
Authority
CR
Costa Rica
Prior art keywords
oprozomib
release formulations
modified release
formulations
release pharmaceutical
Prior art date
Application number
CR20150266A
Other languages
English (en)
Inventor
Mouhannad Jumaa
Naveen Bejugam
Hansen Wong
Christopher J Kirk
Rahul Vishram Manek
Sanjeev Sharma
Tony Muchamuel
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CR20150266A publication Critical patent/CR20150266A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La memoria descriptiva presenta formulaciones farmacéuticas de liberación modificada (por ejemplo, formulaciones farmacéuticas de liberación ampliada; por ejemplo, formas farmacéuticas sólidas, por ejemplo, comprimidos) que son útiles para la administración oral de oprozomib, o una de sus sales farmacéuticamente aceptables, a un sujeto animal o humano así como a métodos de preparar y utilizar dichas formulaciones.
CR20150266A 2012-10-24 2015-05-20 Formulaciones de liberación modificada para oprozomib CR20150266A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261717975P 2012-10-24 2012-10-24
US201261721244P 2012-11-01 2012-11-01
US201361793087P 2013-03-15 2013-03-15
PCT/US2013/066679 WO2014066681A1 (en) 2012-10-24 2013-10-24 Modified release formulations for oprozomib

Publications (1)

Publication Number Publication Date
CR20150266A true CR20150266A (es) 2015-08-14

Family

ID=50485877

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150266A CR20150266A (es) 2012-10-24 2015-05-20 Formulaciones de liberación modificada para oprozomib

Country Status (24)

Country Link
US (2) US9295708B2 (es)
EP (1) EP2912025A4 (es)
JP (1) JP6505604B2 (es)
KR (1) KR20150070406A (es)
CN (1) CN104968650A (es)
AP (1) AP3681A (es)
AR (1) AR093126A1 (es)
AU (1) AU2013334258A1 (es)
BR (1) BR112015008572A2 (es)
CA (1) CA2888039A1 (es)
CL (1) CL2015001085A1 (es)
CR (1) CR20150266A (es)
EA (1) EA201590797A1 (es)
HK (2) HK1208222A1 (es)
IL (1) IL238244A0 (es)
IN (1) IN2015DN03921A (es)
MX (1) MX2015005069A (es)
PE (1) PE20151051A1 (es)
PH (1) PH12015500823A1 (es)
SG (1) SG11201502849XA (es)
TN (1) TN2015000135A1 (es)
TW (1) TW201422255A (es)
UY (1) UY35091A (es)
WO (1) WO2014066681A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
AU2016278846B2 (en) 2015-06-19 2021-08-05 Biotie Therapies, Inc. Controlled-release tozadenant formulations
CN105949279A (zh) * 2016-04-27 2016-09-21 浙江大学 蛋白酶体抑制剂Oprozomib及其类似物的制备方法
CN109641860B (zh) 2016-06-29 2024-05-28 科智生命科学公司 制备肽环氧酮免疫蛋白酶体抑制剂和其前体的方法
WO2018057453A1 (en) 2016-09-21 2018-03-29 Amgen Inc. Immediate release formulations for oprozomib
JP2018123119A (ja) * 2016-12-14 2018-08-09 アムジエン・インコーポレーテツド オプロゾミブのための胃内保持型の徐放性剤形、及びその調製プロセス
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
CN110357940A (zh) * 2019-08-02 2019-10-22 苏州艾和医药科技有限公司 奥普佐米合成工艺研究
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
ATE369330T1 (de) * 2001-02-12 2007-08-15 Wyeth Corp O-desmethyl-venlafaxine succinat salz
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
KR101434522B1 (ko) * 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
WO2007080776A1 (ja) * 2006-01-10 2007-07-19 Kissei Pharmaceutical Co., Ltd. 徐放性製剤およびその製造方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
EP2207791B2 (en) * 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑

Also Published As

Publication number Publication date
AR093126A1 (es) 2015-05-20
EP2912025A4 (en) 2016-06-08
WO2014066681A1 (en) 2014-05-01
IN2015DN03921A (es) 2015-10-02
CN104968650A (zh) 2015-10-07
SG11201502849XA (en) 2015-05-28
US20140113855A1 (en) 2014-04-24
UY35091A (es) 2014-05-30
PH12015500823A1 (en) 2015-06-22
US20160213610A1 (en) 2016-07-28
EP2912025A1 (en) 2015-09-02
US9295708B2 (en) 2016-03-29
AP3681A (en) 2016-04-19
CA2888039A1 (en) 2014-05-01
KR20150070406A (ko) 2015-06-24
IL238244A0 (en) 2015-06-30
MX2015005069A (es) 2015-07-17
AP2015008387A0 (en) 2015-04-30
TW201422255A (zh) 2014-06-16
JP2015535255A (ja) 2015-12-10
EA201590797A1 (ru) 2016-02-29
BR112015008572A2 (pt) 2017-07-04
TN2015000135A1 (en) 2016-10-03
PE20151051A1 (es) 2015-08-03
HK1215709A1 (zh) 2016-09-09
AU2013334258A1 (en) 2015-04-30
HK1208222A1 (en) 2016-02-26
JP6505604B2 (ja) 2019-04-24
CL2015001085A1 (es) 2015-08-28

Similar Documents

Publication Publication Date Title
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
CR20150326A (es) Inhibidores de autotaxina
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
MX354210B (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
ECSP13012368A (es) Composiciones farmacéuticas de co-cristales de tramadol y coxibs
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CY1118032T1 (el) Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112018071370A2 (pt) composições farmacêuticas orais de mesalazina
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
UY36761A (es) Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CR20140293A (es) Preparaciones que comprenden emodepsido amorfo
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación